Russell Investments Group Ltd. Sells 16,450 Shares of United Therapeutics Co. (NASDAQ:UTHR)

Russell Investments Group Ltd. lowered its holdings in United Therapeutics Co. (NASDAQ:UTHR) by 12.4% during the second quarter, HoldingsChannel.com reports. The institutional investor owned 116,338 shares of the biotechnology company’s stock after selling 16,450 shares during the period. Russell Investments Group Ltd.’s holdings in United Therapeutics were worth $25,682,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors also recently added to or reduced their stakes in UTHR. Massmutual Trust Co. FSB ADV boosted its holdings in United Therapeutics by 61.4% in the 2nd quarter. Massmutual Trust Co. FSB ADV now owns 163 shares of the biotechnology company’s stock valued at $36,000 after purchasing an additional 62 shares during the period. Neo Ivy Capital Management bought a new position in United Therapeutics during the second quarter valued at about $48,000. Global Retirement Partners LLC raised its holdings in United Therapeutics by 198.7% in the 1st quarter. Global Retirement Partners LLC now owns 224 shares of the biotechnology company’s stock valued at $49,000 after acquiring an additional 149 shares in the last quarter. Atlas Capital Advisors LLC bought a new stake in shares of United Therapeutics in the 4th quarter worth approximately $51,000. Finally, Archer Investment Corp bought a new stake in shares of United Therapeutics during the first quarter valued at approximately $52,000. 94.08% of the stock is owned by institutional investors.

Insider Activity

In related news, EVP Paul A. Mahon sold 6,000 shares of United Therapeutics stock in a transaction on Thursday, November 2nd. The stock was sold at an average price of $225.76, for a total transaction of $1,354,560.00. Following the completion of the sale, the executive vice president now directly owns 36,599 shares of the company’s stock, valued at $8,262,590.24. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In related news, Director Nilda Mesa sold 383 shares of the business’s stock in a transaction that occurred on Wednesday, September 13th. The stock was sold at an average price of $222.36, for a total value of $85,163.88. Following the completion of the transaction, the director now directly owns 6,303 shares in the company, valued at approximately $1,401,535.08. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Paul A. Mahon sold 6,000 shares of United Therapeutics stock in a transaction that occurred on Thursday, November 2nd. The shares were sold at an average price of $225.76, for a total transaction of $1,354,560.00. Following the completion of the transaction, the executive vice president now directly owns 36,599 shares in the company, valued at approximately $8,262,590.24. The disclosure for this sale can be found here. Insiders have sold a total of 30,383 shares of company stock valued at $6,806,244 in the last 90 days. 12.50% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

UTHR has been the subject of several research reports. StockNews.com cut United Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Friday, November 10th. HC Wainwright reissued a “buy” rating and issued a $300.00 price target on shares of United Therapeutics in a research report on Thursday, August 3rd. JPMorgan Chase & Co. upped their price objective on United Therapeutics from $290.00 to $294.00 and gave the company an “overweight” rating in a research note on Thursday, November 2nd. LADENBURG THALM/SH SH increased their price objective on United Therapeutics from $256.00 to $268.00 and gave the stock a “buy” rating in a research note on Thursday, August 3rd. Finally, Wedbush restated an “outperform” rating and issued a $308.00 target price (up previously from $307.00) on shares of United Therapeutics in a research note on Thursday, November 2nd. One equities research analyst has rated the stock with a sell rating and eight have given a buy rating to the company. According to MarketBeat, United Therapeutics has an average rating of “Moderate Buy” and a consensus target price of $288.00.

United Therapeutics Stock Performance

United Therapeutics stock opened at $228.99 on Tuesday. United Therapeutics Co. has a 12-month low of $204.44 and a 12-month high of $283.09. The company has a quick ratio of 4.51, a current ratio of 4.65 and a debt-to-equity ratio of 0.09. The stock has a 50-day simple moving average of $226.19 and a 200 day simple moving average of $225.97. The stock has a market capitalization of $10.76 billion, a price-to-earnings ratio of 12.62 and a beta of 0.57.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings data on Wednesday, November 1st. The biotechnology company reported $5.38 EPS for the quarter, beating analysts’ consensus estimates of $5.10 by $0.28. The firm had revenue of $609.40 million for the quarter, compared to analyst estimates of $585.82 million. United Therapeutics had a return on equity of 17.10% and a net margin of 40.82%. The business’s quarterly revenue was up 18.1% compared to the same quarter last year. During the same period last year, the company earned $4.91 EPS. On average, research analysts anticipate that United Therapeutics Co. will post 19.36 earnings per share for the current fiscal year.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Tyvaso, an inhaled solution via ultrasonic nebulizer; Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Remunity Pump, a small, lightweight, durable pump and separate controller; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; Unituxin, a monoclonal antibody for treating high-risk neuroblastoma; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.